Survival in dialysis patients is not different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Schroijen, Marielle A ^a   Dekkers, Olaf M ^a   Grootendorst, Diana C ^a   Noordzij, Marlies ^b   Romijn, Johannes A ^a   Krediet, Raymond T ^b   Boeschoten, Elisabeth W ^c   Dekker, Friedo W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Hans Mak Institute   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL VASCULAR DISEASE; RENOVASCULAR DISEASE; RISK ASSESSMENT; SURVIVAL RATE; CHRONIC KIDNEY FAILURE; MIDDLE AGED; NETHERLANDS; PREVALENCE; RENAL REPLACEMENT THERAPY; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NETHERLANDS; PREVALENCE; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 83655196888     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-69     Document Type: Article

References (23)

1. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ, JAMA 1997 278 2069 2074 10.1001/jama.1997.03550230045035 9403420 (Pubitemid 28016228)
2. USRDS. 2001 Annual Data Report. Cooper L, Nephrol News Issues 2001 15 31, 34 35, 38
3. End-stage renal disease attributable to diabetes mellitus. Perneger TV, Brancati FL, Whelton PK, Klag MJ, Ann Intern Med 1994 121 912 918 7978716 (Pubitemid 24370853)
4. The growing volume of diabetes-related dialysis: a population based study. Lok CE, Oliver MJ, Rothwell DM, Hux JE, Nephrol Dial Transplant 2004 19 3098 3103 10.1093/ndt/gfh540 15507475 (Pubitemid 40057634)
5. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Van Dijk PC, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD, Kidney Int 2005 67 1489 1499 10.1111/j.1523-1755.2005.00227.x 15780102 (Pubitemid 40463126)
6. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Vonesh EF, Snyder JJ, Foley RN, Collins AJ, Kidney Int 2004 66 2389 2401 10.1111/j.1523-1755.2004.66028.x 15569331
7. Improved survival rate in patients with diabetes and end-stage renal disease in Denmark. Sorensen VR, Mathiesen ER, Heaf J, Feldt-Rasmussen B, Diabetologia 2007 50 922 929 10.1007/s00125-007-0612-5 17333109 (Pubitemid 46559250)
8. Incidences, treatments, outcomes, and sex effect on survival in patients with end-stage renal disease by diabetes status in Australia and New Zealand (1991 2005). Villar E, Chang SH, McDonald SP, Diabetes Care 2007 30 3070 3076 10.2337/dc07-0895 17848610 (Pubitemid 350255248)
9. Diabetic patients on renal replacement therapy: analysis of Catalan Registry data. Renal Registry Committee. Rodriguez JA, Cleries M, Vela E, Nephrol Dial Transplant 1997 12 2501 2509 10.1093/ndt/12.12.2501 9430842 (Pubitemid 27520665)
10. Renal replacement therapy in patients with diabetic nephropathy, 1980-1985. Report from the European Dialysis and Transplant Association Registry. Brunner FP, Brynger H, Challah S, Fassbinder W, Geerlings W, Selwood NH, Tufveson G, Wing AJ, Nephrol Dial Transplant 1988 3 585 595 3146713 (Pubitemid 19000984)
11. Outcome of renal replacement treatment in patients with diabetes mellitus. McMillan MA, Briggs JD, Junor BJ, BMJ 1990 301 540 544 10.1136/bmj.301.6751.540 2207427 (Pubitemid 20320933)
12. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Van Dijk PC, Jager KJ, de Charro F, Collart F, Cornet R, Dekker FW, Grönhagen-Riska C, Kramar R, Leivestad T, Simpson K, Briggs JD, Nephrol Dial Transplant 2001 16 1120 1129 10.1093/ndt/16.6.1120 11390709 (Pubitemid 32547364)
13. ERA EDTA Registry 2006 Annual report. ERA-EDTA Registry, 2009 Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands, 2008
14. Confounding: what it is and how to deal with it. Jager KJ, Zoccali C, Macleod A, Dekker FW, Kidney Int 2008 73 256 260 10.1038/sj.ki.5002650 17978811
15. The impact of diabetes on patients' survival in dialysis patients with non-diabetic renal disease and in patients who develop diabetes during chronic dialysis. Catalano C, Postorino M, Marino C, Nephrol Dial Transplant 1996 11 1124 1128 8671980 (Pubitemid 26182510)
16. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Liem YS, Wong JB, Hunink MG, de Charro FT, Winkelmayer WC, Kidney Int 2007 71 153 158 10.1038/sj.ki.5002014 17136031 (Pubitemid 46094689)
17. U.S. Renal Data System, USRDS 2008 Annual Report, 2009 Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008
18. Strategies to reduce glucose exposure in peritoneal dialysis patients. Holmes CJ, Shockley TR, Perit Dial Int 2000 20 Suppl 2 37 S41 10911641
19. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW, Kidney Int 2003 64 1480 1486 10.1046/j.1523-1755.2003.00209.x 12969169 (Pubitemid 37153816)
20. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Friedlander MA, Wu YC, Schulak JA, Monnier VM, Hricik DE, Am J Kidney Dis 1995 25 445 451 10.1016/0272-6386(95)90107-8 7872323
21. Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Berrou J, Tostivint I, Verrecchia F, Berthier C, Boulanger E, Mauviel A, Marti HP, Wautier MP, Rondeau E, Hertig A, Int J Mol Med 2009 23 513 520 19288028
22. Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients. Kocak H, Gumuslu S, Sahin E, Ceken K, Gocmen YA, Yakupoglu G, Ersoy FF, Tuncer M, Nephrology (Carlton) 2009 14 273 280 10.1111/j.1440-1797.2008.01062.x
23. Advanced glycation end products: a Nephrologist's perspective. Raj DS, Choudhury D, Welbourne TC, Levi M, Am J Kidney Dis 2000 35 365 380 10.1016/S0272-6386(00)70189-2 10692262